X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://endpts.com/a-star-cancer-scientist-failed-to-disclose-industry-payments-over-the-years-does-that-matter-so-much/
http://www.pmlive.com/pharma_news/novartis_considers_filings_for_pi3k_drug_in_breast_cancer_1249957
https://www.reuters.com/article/us-novartis-breast-cancer/novartis-trial-win-lifts-profile-of-new-breast-cancer-drug-idUSKCN1L80PM
https://endpts.com/novartis-just-boasted-of-a-big-phiii-pi3k-success-but-heres-why-we-should-hold-our-applause-for-now/
https://pharmaphorum.com/news/novartis-success-breast-cancer-inhibitor/
https://endpts.com/novartis-punts-a-late-stage-pi3k-drug-with-a-worrying-safety-profile-to-one-of-chinas-upstart-biotechs/
https://www.fiercebiotech.com/biotech/novartis-hands-off-buparlisib-to-china-s-adlai-noryte
https://www.reuters.com/article/us-health-cancer-roche/roche-drugs-show-limited-benefit-in-lung-breast-cancer-trials-idUSKCN1IY0E4
https://www.fiercebiotech.com/biotech/asco18-roche-punts-taselisib-after-weak-data-severe-side-effects
https://www.biospace.com/article/two-roche-cancer-drugs-get-disappointing-results/
https://endpts.com/roche-dumps-its-phiii-pi3k-effort-on-taselisib-after-researchers-track-poor-survival-edge-harsh-side-effects-for-breast-cancer/
Market Place
Share 
